enGene Therapeutics (ENGN) Total Liabilities (2022 - 2026)

enGene Therapeutics (ENGN) has 5 years of Total Liabilities data on file, last reported at $58.0 million in Q3 2026.

• For the quarter ending Q3 2026, Total Liabilities rose 29.31% year-over-year to $58.0 million; the trailing twelve-month figure through Jul 2026 stood at $58.0 million (up 29.31% YoY), and the FY2025 full-year result was $53.8 million, up 39.41% from the prior year.
• Total Liabilities was $58.0 million for Q3 2026 at enGene Therapeutics, up from $52.4 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $58.0 million in Q3 2026 to a low of $14.5 million in Q4 2023.
• A 5-year average of $41.4 million and a median of $39.4 million in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities sank 69.47% in 2023 and soared 166.43% in 2024, its largest moves.
• enGene Therapeutics' Total Liabilities stood at $47.4 million in 2022, then sank by 69.47% to $14.5 million in 2023, then jumped by 166.43% to $38.6 million in 2024, then surged by 39.41% to $53.8 million in 2025, then increased by 7.95% to $58.0 million in 2026.
• Per Business Quant data, the three most recent Total Liabilities figures were $58.0 million in Q3 2026, $52.4 million in Q2 2026, and $55.6 million in Q1 2026.